Uncovering the roots of Parkinson's disease, together
A global basic research initiative
Aligning Science Across Parkinson’s (ASAP) is fostering collaboration and resources to better understand the underlying causes of Parkinson’s disease. With scale, transparency, and open access data sharing, we believe we can accelerate the pace of discovery, and inform the path to a cure.
GP2’s recently posted sixth data release includes the introduction of a new ancestry group (Complex Admixture History), the introduction of clinical data for ~12,000 individuals, and the introduction of locally restricted GDPR samples via the Verily Viewpoint Workbench.
ASAP launched a Catalyzing Impact page and 35 impact pages for Collaborative Research Network (CRN) teams to highlight their contributions and outputs to the PD research community, along with recognition and engagement in our CRN community.
As we wrap up 2023, we reflect on the results our initiative, network, and supported programs have had on providing new insights into Parkinson’s disease. Together, we have uncovered novel discoveries and made progress toward our vision of advancing collaborative, transparent research processes and environments that deliver faster and better outcomes in PD research.
Latest News
Bearing Down on Parkinson’s
Bloomberg News provides a deep dive into our work and our partnership with The Michael J. Fox Foundation. Working together, we’re proud to be at the forefront of Parkinson’s disease research. Click to view a PDF of the article.
2023 ASAP Collaborative Meeting Series – A Look Back
ASAP’s 2023 Collaborative Meetings welcomed core leadership and trainees from each CRN team to create a space to make connections, share their work, and spark new ideas that spanned career levels, disciplines, and continents. Each event showcased participants who received awards for their work that they presented at the meeting.
Risk factor for Parkinson’s discovered in genes from people of African descent
Read NPR’s coverage of GP2’s historic GBA1 finding. This article by Jon Hamilton includes interviews with ASAP’s Managing Director, Dr. Ekemini A. U. Riley, and lead GP2 study researchers, Andy Singleton and Sara Bandres-Ciga.